Q2 data based on reported April, and May volumes and June based on reiterated guidance ~annualised revenue rate £44 million.
Q3, and Q4 numbers are based on answers from Ben (as per the 29 March 2023 announcement).
There could be additional expenses related to mixed clinical workforce rollout affecting Q2 cash outflow but it will be one-off
Let’s see how truthful Ben Kent’s words are. As per my estimation, DOC will post a £300,000 loss for Q1 24 as well. By then, the annualised revenue will be close to $90 million AUD and even a share price of 0.25 cents should be reasonable.
